Your search returned 2 results.

Results
	1.	Rechallenge of docetaxel combined with epirubicin given on a weekly schedule in advanced castration-resistant prostate cancer patients previously exposed to docetaxel and abiraterone acetate: a single-institution experience. [electronic resource] by Petrioli, R Roviello, G Fiaschi, A I Laera, L Miano, Salvatora T De Rubertis, G Barbanti, G Bianco, V Brozzetti, S Francini, E Producer: 20160425 In: Medical oncology (Northwood, London, England) vol. 32 Online resources: Available from publisher's website Availability: No items available. Save to lists Add to cart (remove)
	2.	Docetaxel and epirubicin compared with docetaxel and prednisone in advanced castrate-resistant prostate cancer: a randomised phase II study. [electronic resource] by Petrioli, R Pascucci, A Conca, R Chiriacò, G Francini, E Bargagli, G Fiaschi, A I Manganelli, A De Rubertis, G Barbanti, G Ponchietti, R Francini, G Producer: 20110502 In: British journal of cancer vol. 104 Online resources: Available from publisher's website Availability: No items available. Save to lists Add to cart (remove)

Refine your search